Spots Global Cancer Trial Database for endometrial adenocarcinoma
Every month we try and update this database with for endometrial adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | NCT03540407 | Cervical Carcin... Cervical Carcin... Cervical Carcin... Endometrial Ade... Endometrial Ade... Endometrial Ade... | Oncoxin-Viusid® Placebo | 18 Years - 80 Years | Catalysis SL | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | NCT03836157 | Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial Cle... | Mirvetuximab So... Bevacizumab | 18 Years - | University of Oklahoma | |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00820898 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Recurrent Uteri... | Gemcitabine Hyd... | 18 Years - | GOG Foundation | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03586661 | Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Copanlisib Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care | NCT03460483 | Endometrial Ade... Endometrial Car... Lynch Syndrome Relatives | Genetic Counsel... Genetic Testing Laboratory Biom... Mutation Carrie... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | NCT00002706 | Endometrial Ade... Stage I Uterine... Stage I Uterine... Stage II Uterin... Stage II Uterin... | Laparoscopic Su... Quality-of-Life... Therapeutic Con... | 18 Years - | GOG Foundation | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | NCT00005830 | Endometrial Ade... Endometrial Cle... Endometrial Ser... Stage III Uteri... Stage IV Uterin... | Doxorubicin Hyd... Cisplatin Radiation Thera... | 18 Years - | GOG Foundation | |
| Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery | NCT00448643 | Endometrial Can... | Vaginal Brachyt... Cisplatin Whole Abdominal... | 18 Years - 80 Years | University of Miami | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery | NCT00002807 | Endometrial Can... | radiation thera... | - 120 Years | Canadian Cancer Trials Group | |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | NCT05112601 | Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom... | Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer | NCT00030485 | Endometrial Can... | erlotinib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | NCT00006089 | Endometrial Ade... ERBB2 Gene Ampl... Recurrent Uteri... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care | NCT03460483 | Endometrial Ade... Endometrial Car... Lynch Syndrome Relatives | Genetic Counsel... Genetic Testing Laboratory Biom... Mutation Carrie... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery | NCT00331760 | Cervical Cancer Endometrial Can... | cisplatin intensity-modul... | 18 Years - | Radiation Therapy Oncology Group | |
| Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors | NCT00004082 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | NCT00002706 | Endometrial Ade... Stage I Uterine... Stage I Uterine... Stage II Uterin... Stage II Uterin... | Laparoscopic Su... Quality-of-Life... Therapeutic Con... | 18 Years - | GOG Foundation | |
| Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | NCT00770185 | Endometrial Can... | ridaforolimus gene expression... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | NCT01005329 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Stage IA Uterin... Stage IB Uterin... Stage II Uterin... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Bevacizumab Carboplatin Cisplatin Intensity-Modul... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | NCT01440998 | Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Endometrioid Ad... Recurrent Uteri... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... | Carboplatin Dasatinib Laboratory Biom... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer | NCT00006027 | Endometrial Can... | cisplatin paclitaxel adjuvant therap... radiation thera... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT01225887 | Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Malignant Uteri... Recurrent Uteri... | Nintedanib | 18 Years - | GOG Foundation | |
| S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | NCT00003127 | Endometrial Can... | amifostine trih... carboplatin paclitaxel | 16 Years - | SWOG Cancer Research Network | |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT01642082 | Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri... | Dalantercept Laboratory Biom... | 18 Years - | GOG Foundation | |
| Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | NCT01943058 | Atypical Endome... Endometrial Ade... Recurrent Endom... Stage IA Endome... Stage IB Endome... Stage II Endome... Stage IIIA Endo... Stage IIIB Endo... Stage IIIC Endo... Stage IVA Endom... Stage IVB Endom... | megestrol aceta... levonorgestrel-... laboratory biom... questionnaire a... | 18 Years - 44 Years | University of Southern California | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery | NCT00448643 | Endometrial Can... | Vaginal Brachyt... Cisplatin Whole Abdominal... | 18 Years - 80 Years | University of Miami | |
| Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer | NCT00002493 | Endometrial Can... Psychosocial Ef... | cisplatin doxorubicin hyd... low-LET photon ... | - | GOG Foundation | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer | NCT00005583 | Endometrial Can... | cisplatin doxorubicin hyd... epirubicin hydr... adjuvant therap... conventional su... radiation thera... | - | National Cancer Institute (NCI) | |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | NCT05112601 | Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom... | Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | NCT00478426 | Endometrial Ade... Endometrial End... Endometrial Ser... Recurrent Uteri... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino... Uterine Corpus ... | Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| PEN-866 in Patients With Advanced Solid Malignancies | NCT03221400 | Carcinoma Endometrial Ade... Neoplasms Squamous Cell C... Adenocarcinoma ... Advanced Cancer Solid Tumor Solid Carcinoma Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Gastric Cancer Gastric Adenoca... Gastroesophagea... Small-cell Lung... Small Cell Lung... Pancreatic Duct... Pancreatic Aden... | PEN-866 Sodium fluorouracil Folinic acid Niraparib | 18 Years - | Tarveda Therapeutics | |
| Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | NCT00064025 | Endometrial Ade... Endometrial Ade... Endometrial End... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... Medroxyprogeste... Therapeutic Con... | 18 Years - | GOG Foundation | |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00820898 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Recurrent Uteri... | Gemcitabine Hyd... | 18 Years - | GOG Foundation | |
| Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00888173 | Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri... | Brivanib Alanin... Laboratory Biom... | 18 Years - | GOG Foundation | |
| Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00025467 | Endometrial Ade... Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Pap... Recurrent Endom... | thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| Prognostic Biomarkers in Patients With Endometrial Cancer | NCT01208467 | Endometrial Ade... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... | - | GOG Foundation | |
| Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | NCT00087100 | Endometrial Can... | pemetrexed diso... | - | GOG Foundation | |
| Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | NCT01943058 | Atypical Endome... Endometrial Ade... Recurrent Endom... Stage IA Endome... Stage IB Endome... Stage II Endome... Stage IIIA Endo... Stage IIIB Endo... Stage IIIC Endo... Stage IVA Endom... Stage IVB Endom... | megestrol aceta... levonorgestrel-... laboratory biom... questionnaire a... | 18 Years - 44 Years | University of Southern California | |
| Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | NCT00072176 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Pap... Recurrent Endom... Stage IIIA Endo... Stage IIIB Endo... Stage IIIC Endo... Stage IVA Endom... Stage IVB Endom... | temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | NCT00005830 | Endometrial Ade... Endometrial Cle... Endometrial Ser... Stage III Uteri... Stage IV Uterin... | Doxorubicin Hyd... Cisplatin Radiation Thera... | 18 Years - | GOG Foundation | |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT01935973 | Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Uteri... | Laboratory Biom... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Improving the Treatment for Women With Early Stage Cancer of the Uterus | NCT01686126 | Complex Endomet... Grade 1 Endomet... | Levonorgestrel Metformin | 18 Years - | Queensland Centre for Gynaecological Cancer | |
| Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer | NCT00870337 | Endometrial Can... | everolimus | 18 Years - | ARCAGY/ GINECO GROUP | |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05325866 | Solid Tumors | Bemarituzumab | 18 Years - 99 Years | Amgen | |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | NCT00003624 | Cervical Cancer Endometrial Can... Fallopian Tube ... Neurotoxicity Ovarian Cancer Primary Periton... Sarcoma | amifostine trih... cisplatin paclitaxel | - | GOG Foundation | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | NCT00002976 | Endometrial Can... | conjugated estr... | - | GOG Foundation | |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | NCT00003624 | Cervical Cancer Endometrial Can... Fallopian Tube ... Neurotoxicity Ovarian Cancer Primary Periton... Sarcoma | amifostine trih... cisplatin paclitaxel | - | GOG Foundation | |
| Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines | NCT03164590 | Endometrial Ade... | Ketamine dexmedetomidine bupivacaine | 18 Years - 60 Years | Assiut University | |
| [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer | NCT04972682 | Endometrial Can... Endometrial Neo... Endometrial Ade... Endometrial Can... Endometrial Can... Endometrial End... Sentinel Lymph ... Hysterectomy Laparoscopic Hy... | Laparoscopic to... | 18 Years - | Moscow City Oncology Hospital No. 62 | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer | NCT01150682 | Endometrial Can... | RNA analysis reverse transcr... enzyme-linked i... immunohistochem... laboratory biom... | - | National Cancer Institute (NCI) | |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | NCT01005329 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Stage IA Uterin... Stage IB Uterin... Stage II Uterin... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Bevacizumab Carboplatin Cisplatin Intensity-Modul... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | NCT00006011 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Ser... Stage III Uteri... | Doxorubicin Hyd... Cisplatin Filgrastim Pegfilgrastim Paclitaxel | - | GOG Foundation | |
| PErsonalized TReatment for Endometrial Carcinoma | NCT05655260 | Endometrial Ade... | Comparison of a... Comparison of a... | 18 Years - 100 Years | University of Helsinki | |
| Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00095979 | Endometrial Ade... Recurrent Endom... Stage IV Endome... | ixabepilone | - | National Cancer Institute (NCI) | |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | NCT01041027 | Endometrial Ade... Stage IA Uterin... Stage IB Uterin... Stage II Uterin... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Paclitaxel Carboplatin Internal Radiat... External Beam R... Laboratory Biom... | 18 Years - | Albert Einstein College of Medicine | |
| Prognostic Biomarkers in Patients With Endometrial Cancer | NCT01208467 | Endometrial Ade... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... | - | GOG Foundation | |
| Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00025467 | Endometrial Ade... Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Pap... Recurrent Endom... | thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | NCT05001282 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Endometrial Can... Ovary Cancer Ovary Neoplasm Ovary Disease Ovary Metastasi... Ovarian Disease... Ovarian Cancer ... Ovarian Epithel... Ovarian Adenoca... Ovarian Serous ... Ovarian Neoplas... Ovarian Cancer ... Endometrial Dis... Endometrial Ade... Endometrial Car... Endometrial Cle... Endometrioid Ad... Endometrial Neo... Endometrial Can... Endometrioid Tu... Fallopian Tube ... Peritoneal Canc... | ELU001 | 18 Years - | Elucida Oncology | |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT01132820 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri... | Cediranib Malea... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | NCT06399757 | Colorectal Canc... Cholangiocarcin... Appendiceal Ade... Pancreatic Aden... Gastric Adenoca... Endometrial Ade... Triple Negative... Ovarian Cancer Prostate Cancer | APL-5125 | 18 Years - | Apollo Therapeutics Ltd | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | NCT03836157 | Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial Cle... | Mirvetuximab So... Bevacizumab | 18 Years - | University of Oklahoma | |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | NCT05112601 | Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom... | Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer | NCT00004251 | Endometrial Can... | letrozole | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer | NCT00002493 | Endometrial Can... Psychosocial Ef... | cisplatin doxorubicin hyd... low-LET photon ... | - | GOG Foundation | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Pembro/Carbo/Taxol in Endometrial Cancer | NCT02549209 | Endometrial Can... Endometrial Ade... | Pembrolizumab Paclitaxel Carboplatin | 18 Years - | Big Ten Cancer Research Consortium | |
| Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines | NCT03164590 | Endometrial Ade... | Ketamine dexmedetomidine bupivacaine | 18 Years - 60 Years | Assiut University | |
| Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | NCT00006089 | Endometrial Ade... ERBB2 Gene Ampl... Recurrent Uteri... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | NCT01005329 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Stage IA Uterin... Stage IB Uterin... Stage II Uterin... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Bevacizumab Carboplatin Cisplatin Intensity-Modul... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | NCT01307631 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri... | Akt Inhibitor M... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | NCT01210222 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Ser... Endometrioid St... Recurrent Uteri... | Trebananib | 18 Years - | GOG Foundation | |
| Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00095979 | Endometrial Ade... Recurrent Endom... Stage IV Endome... | ixabepilone | - | National Cancer Institute (NCI) | |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | NCT00977574 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Bevacizumab Carboplatin Ixabepilone Laboratory Biom... Paclitaxel Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | NCT00064025 | Endometrial Ade... Endometrial Ade... Endometrial End... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin... | Laboratory Biom... Medroxyprogeste... Therapeutic Con... | 18 Years - | GOG Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
